Bristol-Myers Squibb Stock Falls After Results of Cancer Treatment Study Disappoint -- Barrons.com | BMY Message Board Posts

Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  604 of 3397  at  7/24/2019 8:29:00 PM  by

jerrykrause


Bristol-Myers Squibb Stock Falls After Results of Cancer Treatment Study Disappoint -- Barrons.com

Bristol-Myers Squibb Stock Falls After Results of Cancer Treatment Study Disappoint -- Barrons.com  
 
Dow Jones
 
By Teresa Rivas

Bristol-Myers Squibb stock (ticker: BMY) fell in after-hours trading Wednesday, on the back of disappointing data for a combination cancer treatment with its drugs Opdivo and Yervoy.

The back story. It's already been a tough year for Bristol-Myers. The stock is down 16.8% in 2019 through the close of regular trading Wednesday, and has fallen nearly 27% in the trailing 12-month period. Disappointing drug data has played a role, but most of the decline is because of the company's acquisition of Celgene (CELG). The deal has been a magnet for critics and investor opposition, and has been beset by delays and regulatory issues.

What's new. After the close of regular trading Wednesday, Bristol-Myers reported results from its CheckMate 227 study. The first part of the study met one of its primary goals, with low-dose Yervoy and Opdivo demonstrating superiority to chemotherapy as an initial treatment for non-small cell lung cancer patients with a specific tumor profile.

However, part two of the Phase 3 trial didn't meet its endpoint of overall survival with Opdivo plus chemotherapy versus just chemotherapy in another group of lung cancer patients. Bristol-Myers promised to share complete findings from the study at an coming medical meeting.

Looking ahead. It isn't entirely surprising that Bristol is trading down on the news. Amid Celgene-related concerns, investors are also worried about patent losses for the company, which means there additional hopes are pinned on the company's pipeline. A more robust result may have put investors' minds at ease.

In addition, Opdivo was a steady performer in Bristol-Myers' most recent quarter. A good trial would have opened up a new sales outlet for the drug. The news comes just a month after Bristol-Myers said reported that another Phase 3 trial involving Opdivo also didn't meet its primary endpoint.

Bristol-Myers was down 4.6% to$41.24 in recent trading 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 137
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
612 Re: Bristol-Myers Squibb Stock Falls After Results of Cancer Treatment Study Disappoint -- Barrons.com tocentsworth 0 7/25/2019 11:19:43 AM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...